Table 2.
CD45RO+CD25bright | CD45RO-CD25dim | |||
---|---|---|---|---|
PBL | HLA-DR+ | HLA-DR− | HLA-DR+ | HLA-DR− |
Mean % positive ± SEM (Mean Fluorescent Intensity FOXP3 ± SEM) | ||||
NSCLC patients | 20 ± 3 (9,477 ± 608) | 80 ± 3 (6,851 ± 357)* | 9 ± 2 (19,794 ± 10,299) | 90 ± 2 (3,030 ± 325)** |
Control subjects | 17 ± 3 (8,265 ± 1,025) | 83 ± 3 (5,579 ± 261) | 11 ± 3 (11,452 ± 6,463) | 88 ± 0.7 (1,854 ± 271) |
p≤0.006 compared to control;
p≤0.007 compared to control